Metabolic signalling
Tirzepatide
What is it?
Tirzepatide is a synthetic peptide designed to activate both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. These receptors participate in the regulation of food intake and blood glucose. It is distinct from semaglutide, which targets GLP-1 alone, and retatrutide, which also targets the glucagon receptor.
How it is studied
Receptor activation influences glucose-dependent insulin secretion, glucagon regulation and signals involved in appetite. Tirzepatide also delays gastric emptying. Its effects reflect a combination of receptor signalling and changes in food intake rather than a direct, selective removal of body fat.
What the evidence shows
Prescription tirzepatide medicines have been evaluated in controlled human trials. The official Mounjaro product information describes a defined medicine for type 2 diabetes; it specifies the formulation, manufacturing controls, eligible population and safety monitoring. That evidence concerns the tested medicinal product.
Limitations & safety context
Important labelled concerns include gastrointestinal reactions, pancreatitis, gallbladder disease and dehydration-related kidney injury. Low blood glucose is more likely with certain other diabetes medicines. The label includes a thyroid C-cell tumour warning based on animal findings and contraindications for particular thyroid-cancer histories. A supplier vial cannot be assumed equivalent to Mounjaro.
Listed specifications
| Reference | Listed contents |
|---|---|
| T10 | 10 mg |
| T15 | 15 mg |
| T20 | 20 mg |
| T30 | 30 mg |
| T40 | 40 mg |
| T50 | 50 mg |
| T60 | 60 mg |
| T100 | 100 mg |
| T120 | 120 mg |
Source-document quantities, not doses or a confirmation of stock. Identity, purity, component composition and suitability require separate documentation.
Research information only. No dosing, administration or treatment advice.